Verona Pharma(VRNA) - 2022 Q4 - Annual Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR | Title of each class | Trading Symbol | Name of each exchange on which registered | | --- | --- | --- | | Ordinary shares, nominal value £0.05 per share* | VRNA | The Nasdaq Stock Market LLC (Nasdaq Global Market) | ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ...